Drugs / EZOBRESIB
EZOBRESIB
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03936465 | Sep 2019 → Mar 2024 | brain cancer, childhood malignant neoplasm, lymphoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05372354 | Oct 2022 → Oct 2026 expected | plasma cell myeloma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04817007 | Mar 2021 → Aug 2028 expected | myelofibrosis | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02419417 | Jun 2015 → Mar 2021 | metastatic neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-06-12 | Bristol-Myers Squibb | Results Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025 bms.com ↗
35% for mezigdomide plus BET inhibitor BMS-986158 and dexamethasone (n=20) |
| 2023-05-11 | Bristol-Myers Squibb | Results Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023 bms.com ↗
Results from the dose-escalation components of a Phase 1/2 study evaluating BET inhibitor BMS-986158 as monotherapy and in combination with ruxolitinib or Inrebic (fedratinib), show generally manageable safety and robust spleen volume reduction in patients with intermediate- or high-risk myelofibrosis. |
All press releases naming this drug 2 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EZOBRESIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297458 ↗ |
| Known as | Bet inhibitor bms-986158 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297458 ↗ |
| Known as | BMS-986158 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03936465 ↗ |
| Action | Inhibit | “a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins” NCT02419417 ↗ |
| Modality | Small molecule | “a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins” NCT02419417 ↗ |
| Route | Oral | “Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.” NCT03936465 ↗ |